The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary?

IF 1.5 4区医学 Q4 IMMUNOLOGY

Central European Journal of Immunology Pub Date : 2023-01-01 DOI:10.5114/ceji.2023.126206

Adam Tworek, Krzysztof Jaroń, Małgorzata Cicha, Andrzej Rydzewski, Waldemar Wierzba, Artur Zaczyński, Zbigniew Król, Grażyna Rydzewska

{"title":"The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary?","authors":"Adam Tworek, Krzysztof Jaroń, Małgorzata Cicha, Andrzej Rydzewski, Waldemar Wierzba, Artur Zaczyński, Zbigniew Król, Grażyna Rydzewska","doi":"10.5114/ceji.2023.126206","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of this study was to investigate the persistence of SARS-CoV-2 neutralizing antibodies (NAbs) one year after contracting COVID-19.Material and methods: The study included 38 patients - 34 men and 4 women - suffering from COVID-19 between March 15 and May 26, 2020. The median age in the group was 31 years, ranging from 22 to 67 years. The levels of neutralizing antibodies were measured at three time-points - baseline, 6 months, and 12 months. The primary endpoint was a post-infection positive result for NAbs (> 15 AU/ml; Liaison SARS-CoV-2 S1/S2 IgG quantitative test) 12 months after infection.Results: The median level of NAbs after 12 months was 26.5 AU/ml. At the end of observation (12 months), 21 of the 38 patients had a NAb level of >15 AU/ml (positive). The median antibody half-life was 5.8 months.Conclusions: A high percentage of the patients maintained positive levels of antibodies 6 and 12 months after COVID-19 infection. The dynamics of the antibody level decline suggests the need for booster vaccination at least once a year.","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 2","pages":"92-96"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/7d/CEJI-48-50430.PMC10485689.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ceji.2023.126206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The aim of this study was to investigate the persistence of SARS-CoV-2 neutralizing antibodies (NAbs) one year after contracting COVID-19.

Material and methods: The study included 38 patients - 34 men and 4 women - suffering from COVID-19 between March 15 and May 26, 2020. The median age in the group was 31 years, ranging from 22 to 67 years. The levels of neutralizing antibodies were measured at three time-points - baseline, 6 months, and 12 months. The primary endpoint was a post-infection positive result for NAbs (> 15 AU/ml; Liaison SARS-CoV-2 S1/S2 IgG quantitative test) 12 months after infection.

Results: The median level of NAbs after 12 months was 26.5 AU/ml. At the end of observation (12 months), 21 of the 38 patients had a NAb level of >15 AU/ml (positive). The median antibody half-life was 5.8 months.

Conclusions: A high percentage of the patients maintained positive levels of antibodies 6 and 12 months after COVID-19 infection. The dynamics of the antibody level decline suggests the need for booster vaccination at least once a year.

Abstract Image

查看原文本刊更多论文

COVID-19后SARS-CoV-2中和抗体的持久性:一年观察是否有必要接种SARS-CoV-2强化疫苗?

本研究的目的是研究SARS-CoV-2中和抗体(nab)在感染COVID-19一年后的持久性。材料和方法:该研究包括38名患者，34名男性和4名女性，他们在2020年3月15日至5月26日期间患有COVID-19。患者年龄中位数为31岁，年龄范围从22岁到67岁不等。在基线、6个月和12个月三个时间点测量中和抗体的水平。主要终点是感染后nab阳性结果(> 15 AU/ml;感染后12个月联络SARS-CoV-2 S1/S2 IgG定量检测。结果:12个月后nab的中位水平为26.5 AU/ml。观察结束时(12个月)，38例患者中有21例NAb水平>15 AU/ml(阳性)。抗体的中位半衰期为5.8个月。结论:患者在COVID-19感染后6个月和12个月抗体保持阳性的比例较高。抗体水平下降的动态提示需要每年至少加强一次疫苗接种。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊